Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Jason S. Kirk, Kevin Schaarschuch, Zafardjan Dalimov, Elena Lasorsa, Sheng Yu Ku, Swathi Ramakrishnan, Qiang Hu, Gissou Azabdaftari, Jianmin Wang, Roberto Pili, Leigh Ellis

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic. Therefore novel therapies are urgently required. We conducted RNA-seq using tumors from a unique murine transplant mouse model which spontaneously progresses to metastatic disease. Differential gene expression analysis revealed a significant increase of topoisomerase IIa, Top2a (Top2a) in metastatic tumors. Interrogation of human data revealed that increased Top2a expression in primary tumors selected patients with more aggressive disease. Further, significant positive correlation was observed between Top2a and the histone methyltransferase, Ezh2. Combination of the Top2 poison etoposide with the Ezh2 inhibitor GSK126 or DZNep significantly increased cell death in vitro in murine and human prostate cancer cell lines. Additionally, combination therapy extended time to progression and increased therapeutic efficacy in vivo. Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. In addition, our data suggests that this combination therapeutic strategy is beneficial against aggressive PCa, and provides strong rationale for continued clinical development.

Original languageEnglish (US)
Pages (from-to)3136-3146
Number of pages11
JournalOncotarget
Volume6
Issue number5
StatePublished - 2015
Externally publishedYes

Fingerprint

Epigenomics
Prostatic Neoplasms
Etoposide
Therapeutics
Neoplasms
Poisons
Androgen Receptors
Cell Death
RNA
Transplants
Gene Expression
Cell Line

Keywords

  • Epigenetics
  • Etoposide
  • Ezh2
  • Prostate cancer
  • Therapy
  • Top2a

ASJC Scopus subject areas

  • Oncology

Cite this

Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S. Y., Ramakrishnan, S., ... Ellis, L. (2015). Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget, 6(5), 3136-3146.

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. / Kirk, Jason S.; Schaarschuch, Kevin; Dalimov, Zafardjan; Lasorsa, Elena; Ku, Sheng Yu; Ramakrishnan, Swathi; Hu, Qiang; Azabdaftari, Gissou; Wang, Jianmin; Pili, Roberto; Ellis, Leigh.

In: Oncotarget, Vol. 6, No. 5, 2015, p. 3136-3146.

Research output: Contribution to journalArticle

Kirk, JS, Schaarschuch, K, Dalimov, Z, Lasorsa, E, Ku, SY, Ramakrishnan, S, Hu, Q, Azabdaftari, G, Wang, J, Pili, R & Ellis, L 2015, 'Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer', Oncotarget, vol. 6, no. 5, pp. 3136-3146.
Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku SY, Ramakrishnan S et al. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 2015;6(5):3136-3146.
Kirk, Jason S. ; Schaarschuch, Kevin ; Dalimov, Zafardjan ; Lasorsa, Elena ; Ku, Sheng Yu ; Ramakrishnan, Swathi ; Hu, Qiang ; Azabdaftari, Gissou ; Wang, Jianmin ; Pili, Roberto ; Ellis, Leigh. / Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. In: Oncotarget. 2015 ; Vol. 6, No. 5. pp. 3136-3146.
@article{38bf358e005c4244bdf5c5975ddb4575,
title = "Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer",
abstract = "Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic. Therefore novel therapies are urgently required. We conducted RNA-seq using tumors from a unique murine transplant mouse model which spontaneously progresses to metastatic disease. Differential gene expression analysis revealed a significant increase of topoisomerase IIa, Top2a (Top2a) in metastatic tumors. Interrogation of human data revealed that increased Top2a expression in primary tumors selected patients with more aggressive disease. Further, significant positive correlation was observed between Top2a and the histone methyltransferase, Ezh2. Combination of the Top2 poison etoposide with the Ezh2 inhibitor GSK126 or DZNep significantly increased cell death in vitro in murine and human prostate cancer cell lines. Additionally, combination therapy extended time to progression and increased therapeutic efficacy in vivo. Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. In addition, our data suggests that this combination therapeutic strategy is beneficial against aggressive PCa, and provides strong rationale for continued clinical development.",
keywords = "Epigenetics, Etoposide, Ezh2, Prostate cancer, Therapy, Top2a",
author = "Kirk, {Jason S.} and Kevin Schaarschuch and Zafardjan Dalimov and Elena Lasorsa and Ku, {Sheng Yu} and Swathi Ramakrishnan and Qiang Hu and Gissou Azabdaftari and Jianmin Wang and Roberto Pili and Leigh Ellis",
year = "2015",
language = "English (US)",
volume = "6",
pages = "3136--3146",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

AU - Kirk, Jason S.

AU - Schaarschuch, Kevin

AU - Dalimov, Zafardjan

AU - Lasorsa, Elena

AU - Ku, Sheng Yu

AU - Ramakrishnan, Swathi

AU - Hu, Qiang

AU - Azabdaftari, Gissou

AU - Wang, Jianmin

AU - Pili, Roberto

AU - Ellis, Leigh

PY - 2015

Y1 - 2015

N2 - Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic. Therefore novel therapies are urgently required. We conducted RNA-seq using tumors from a unique murine transplant mouse model which spontaneously progresses to metastatic disease. Differential gene expression analysis revealed a significant increase of topoisomerase IIa, Top2a (Top2a) in metastatic tumors. Interrogation of human data revealed that increased Top2a expression in primary tumors selected patients with more aggressive disease. Further, significant positive correlation was observed between Top2a and the histone methyltransferase, Ezh2. Combination of the Top2 poison etoposide with the Ezh2 inhibitor GSK126 or DZNep significantly increased cell death in vitro in murine and human prostate cancer cell lines. Additionally, combination therapy extended time to progression and increased therapeutic efficacy in vivo. Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. In addition, our data suggests that this combination therapeutic strategy is beneficial against aggressive PCa, and provides strong rationale for continued clinical development.

AB - Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic. Therefore novel therapies are urgently required. We conducted RNA-seq using tumors from a unique murine transplant mouse model which spontaneously progresses to metastatic disease. Differential gene expression analysis revealed a significant increase of topoisomerase IIa, Top2a (Top2a) in metastatic tumors. Interrogation of human data revealed that increased Top2a expression in primary tumors selected patients with more aggressive disease. Further, significant positive correlation was observed between Top2a and the histone methyltransferase, Ezh2. Combination of the Top2 poison etoposide with the Ezh2 inhibitor GSK126 or DZNep significantly increased cell death in vitro in murine and human prostate cancer cell lines. Additionally, combination therapy extended time to progression and increased therapeutic efficacy in vivo. Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. In addition, our data suggests that this combination therapeutic strategy is beneficial against aggressive PCa, and provides strong rationale for continued clinical development.

KW - Epigenetics

KW - Etoposide

KW - Ezh2

KW - Prostate cancer

KW - Therapy

KW - Top2a

UR - http://www.scopus.com/inward/record.url?scp=84923296051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923296051&partnerID=8YFLogxK

M3 - Article

C2 - 25605014

AN - SCOPUS:84923296051

VL - 6

SP - 3136

EP - 3146

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -